AbbVie (NYSE: ABBV)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
AbbVie Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AbbVie Company Info
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products.
News & Analysis
These two blue-chip dividend stocks offer investors a reliable income stream in a volatile market.
Thinking long-term could pay off now for AbbVie investors.
AbbVie shares rose in the double digits last year.
Long-term investors shouldn't hesitate to add these stocks to their portfolios.
A list of high-yielding dividend stocks to consider buying now.
High-growth industries are risky, but they also have tremendous potential.
AbbVie stock and earnings have increased over time.
Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/24/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ABBV earnings call for the period ending December 31, 2022.
ABBV earnings call for the period ending September 30, 2022.
ABBV earnings call for the period ending June 30, 2022.
ABBV earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.